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Gap junctional intercellular communication (GJIC) regulates cellular homeostasis by propagating
signaling molecules, exchanging cellular metabolites, and coupling electrical signals. In cancer, cells
exhibit altered rates of GJIC which may play a role in neoplastic progression. KATP channels help
maintain membrane polarity and linkages between KATP channel activity and rates of GJIC have been
established. The mechanistic relationship has not been fully elucidated. We report the effects of
treatment with multiple KATP antagonist compounds on GJIC in metastatic cell lines demonstrating
an increase in communication rates following treatment with compounds possessing speciﬁcities
towards the SUR2 subunit of KATP. These effects remained consistent using cell lines with different
expression levels of SUR1 and SUR2, suggesting possible off target effects on GJIC by these
compounds.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Gap junctional intercellular communication (GJIC) is a process
by which cells communicate soluble factors and electrical signals
through physical interactions at the plasma membrane via regu-
lated channels known as connexons [1]. Connexons are hexameric
structures comprised of a family of monomeric proteins, connex-
ins. More than 20 connexin proteins have been reported in mam-
malian cells, each which varying speciﬁcities of regulation. Once
assembled in the plasma membrane connexon channels can be
opened or closed through a variety of signals including cellular
pH, ion concentrations, and ATP levels [2–4]. From a metabolic per-chemical Societies. Published by E
SA, bovine serum albumin;
ine serum; GJIC, gap junction
ecyl sulfate–polyacrylamide
S-buffered saline Tween-20;
nt of Cancer Biology, Kansas
edical Center, 3901 Rainbow
ter, Northwestern University,spective, exchange of small molecules (<1.5 kDa) between these
channels allows cells to share nutrients and secondary signaling
molecules (e.g. IP3), in addition to regulating multiple cell types
(e.g. cardiac, neuronal, and epithelial) through electrical communi-
cation contributing to the coordination of tissue function.
While GJIC is a means for normal cellular homeostasis, in cancer
cells this communication is often dysregulated. Initially, reports
demonstrated that during neoplastic progression, GJIC between
cancer cells was often reduced compared to non-transformed cells
of the same origin [5–7]. More recently however, it is appreciated
that GJIC may also be increased in cancer cells, or between cancer
cells and stromal cells at secondary metastatic sites, highlighting
cell and tissue context speciﬁc events [8–10]. In any case, altera-
tions of the level of GJIC between cancer cells is commonly
observed.
The ATP sensitive potassium channel (KATP) regulates K+ con-
ductance in cells and is closed by increasing concentrations of
ATP. Closure of these channels results in depolarization of the plas-
ma membrane due to reduced potassium conductance. The struc-
ture of the KATP channel is composed of an inwardly rectifying
potassium channel KIR (KIR6.1, KIR6.2), and a sulfonylurea subunit
(SUR1, SUR2A and SUR2B) which regulate the activity of KIR
through sensitivity to ATP levels, as well as other metaboliteslsevier B.V. All rights reserved.
28 T.M. Bodenstine et al. / FEBS Letters 586 (2012) 27–31(e.g. PIP2) [11]. Growing evidence has supported a role for KATP in
the regulation of GJIC activity. Vera et al. initially demonstrated
that reduction of endogenous ATP levels (which would relieve KATP
inhibition) decreased GJIC in astrocytes and this effect was revers-
ible [12]. Further work showed that closure of KATP channels by the
sulfonylurea receptor inhibitors tolbutamide and glibenclamide
leads to increases in GJIC, suggesting that KATP may play a regula-
tory role in opening of connexon channels, possibly through mech-
anisms related to membrane depolarization [13,14]. Collectively
these studies proposed evidence that inhibition of KATP channels
leads to greater rates of GJIC between cells, while opening of the
same channels decreases GJIC. These data provide a link to the
metabolic regulation of gap junctions through ATP. Additionally,
development of tolbutamide as a therapeutic agent for cancer
treatment through its effects on connexin regulation and gap junc-
tion modulation remains promising [15–18]. Interestingly how-
ever, an increased risk of cancer mortality in Type 2 diabetes
patients administered sulfonylureas has been reported [19,20],
implicating context-dependent mechanisms and a possible role
for modulation of KATP conductance in the progression of cancer.
In the present study we examined the effect of treatment of
highly metastatic cancer cell lines (MDA-MB-231, MDA-MB-435,
and C8161.9), which exhibit low baseline gap junction activity, with
KATP inhibitory compounds. Treatment of cellswith the sulfonylurea
receptor inhibitor glibenclamide produced a robust and consistent
increase in calcein dye transfer indicative of GJIC between cancer
cells expressing detectable protein levels of SUR2 with little to no
detection of SUR1. Upon further examination of additional KATP
inhibitors with the MDA-MB-231 breast carcinoma cell line, we
found that inhibitors with dual speciﬁcities to both the SUR1 and
SUR2 subunits increased GJIC while those with primary speciﬁcities
to SUR1 had little to no effect on GJIC suggesting that inhibition of
SUR2KATP channelswas responsible for the increase in GJIC. To eval-
uate this hypothesis, we screened additional breast cancer cell lines
and identiﬁed the SUM159 as expressing inverse levels of SUR1 and
SUR2compared toMDA-MB-231,MDA-MB-435 andC8161.9. Treat-
ment of SUM159 with the KATP inhibitors resulted in the same pat-
tern of GJIC. These data suggest the possibility of novel effects on
GJIC by KATP inhibitors that are independent of their KATP speciﬁcity
andwill be important for future studies involving these compounds.
2. Materials and methods
2.1. Cell lines
MDA-MB-231, MDA-MB-435 and C8161.9 were grown in Dul-
becco’s-modiﬁed Eagle’s medium mixed 1:1 (v:v) with Ham’s F-
12 medium (DMEM/F12, Invitrogen #11330) supplemented withFig. 1. Treatment of cancer cells with glibenclamide increases gap junction communicati
(green) and DiI (red) and co-cultured with non-labeled acceptor cells in the absence or p
cells to acceptor cells. B) Quantiﬁcation of calcein/DiI assays measuring dye transfer from
C8161.9 cancer cell lines. Results are represented as fold change between non-treated
receiving calcein per donor cell. (⁄P < 0.05, error bars represent mean ± standard deviati2 mmol/l L-glutamine, 0.2 mmol/l non-essential amino acids and
5% fetal bovine serum (FBS). MDA-MB-231 and MDA-MB-435 are
human breast carcinoma-derived cell lines. For the origin of
MDA-MB-435 the reader is referred to Chambers, Can Res, 2009
[21]. The C8161.9 is a clone derived from the C8161 human mela-
noma. The SUM159 cell line was a generous gift provided by the
laboratory of David Salomon, National Cancer Institute. SUM159
were maintained in Ham’s F12 media (Invitrogen #11765) supple-
mented with 5 lg/ml insulin, 0.1 lg/ml epidermal growth factor,
10 mmol/l HEPES and 10% fetal bovine serum. All cell lines were
tested for Mycoplasma spp. contamination using PCR (#302108;
Aligent Technologies, Santa Clara, CA).
2.2. Chemicals
The following chemicals were obtained from Sigma (chlorprop-
amide #C1290, glibenclamide #G0639, gliclazide #G6127, glim-
epiride #G2295, repaglinide #R9028, tolbutamide #T0891).
Calcein-AM #C1430 and 1,10-dilinoleyl-3,3,30,30-tetramethylindo-
carbocyanine (DiI) #C7001 were purchased from Invitrogen.
All compounds were dissolved in DMSO, aliquoted and frozen at
20 C. At time of experiments aliquots were thawed and working
concentrations made fresh. DMSO alone (NT, non-treated) had no
effect on dye transfer. No morphological changes or signs of toxic-
ity were observed for each compound/dose reported in this study.
2.3. GJIC assay
Gap junction assays were performed as previously described
[22]. ‘‘Donor’’ cells were loaded with Calcein-AM and DiI, a lipo-
philic dye that does not transfer between cells used to mark donor
cells. After washing three times with Dulbecco’s phosphate buf-
fered saline (DPBS), donor cells were plated with non-labeled
‘‘acceptor’’ cells for 6 h. Calcein spread from donor to acceptor cells
was indicative of GJIC. All experiments reported herein were con-
ducted in serum-free media in order to observe the effects of KATP
inhibitors in the absence of additional growth factors. Flow cytom-
etry with a BD LSRII Cell analytic ﬂow cytometer using BD FACS
Diva software was used to calculate the average number of cells
that received calcein per donor cell and represented as fold change.
2.4. Immunoblot assay and antibodies
Cells were lysed in buffer containing 25 mmol/l Tris
(tris(hydroxymethyl)aminomethane), 1% Triton-X100, 500 mmol/l
b-glycerolphosphate, 0.5 mmol/l EDTA and 5% glycerol on ice fol-
lowed by sonication to disrupt cell membranes. Lysates were re-
solved by 12% SDS–PAGE and transferred to PVDF membranes.
Antibodies to SUR1 (Abcam #ab32844) and SUR2 (BD Pharmigenon. (A) Representative images of metastatic C8161.9 donor cells labeled with calcein
resence of 10 lmol/l glibenclamide. Calcein can be visualized spreading from donor
donor to acceptor cells using ﬂow cytometry in MDA-MB-231, MDA-MB-435 and
(NT) and glibenclamide treated groups measuring the number of acceptor cells
on).
Fig. 3. Immunoblot analysis of SUR1 and SUR2 in lysates from MDA-MB-231, MDA-
MB-435 and C8161.9. Whole cell lysates were collected from indicated cancer cell
lines and probed for the expression of SUR1 and SUR2. SUR2 expression was readily
detected in each cell line, however SUR1 protein could not be detected in MDA-MB-
231 and MDA-MB-435 with minimal detection in C8161.9.
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(BSA) in Tris-buffered saline Tween-20 (TBST) overnight at 4 C fol-
lowed by incubation with horse radish peroxidase (HRP) conju-
gated anti-mouse (GE Healthcare #NXA931) or conjugated anti-
rabbit (GE Healthcare #NA934) at 1:2500 in 5% non-fat dry milk
in TBST for 3 h at room temperature. Membranes were developed
with ECL (Thermo Scientiﬁc #32209). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) HRP-conjugated antibody (AbCam
#ab9385) and Alpha Actin (Millipore #1501) were used for equal
loading control.
2.5. Statistical analysis
Data for GJIC are presented as mean ± standard deviation and
represented as fold change compared to non-treated (NT) group.
Student t-test was used for statistical analysis between groups.
3. Results and discussion
Dysregulation of gap junction coupling is a phenotypic alter-
ation commonly observed in neoplastic cells. We and others have
previously demonstrated a speciﬁc loss of homotypic and hetero-
typic GJIC in metastatic cells [22–24]. While the dysregulation of
GJIC in neoplastic cells is apparent, the speciﬁc signaling events
and the mediators of those signaling events between malignant
cells or between malignant cells and the surrounding stromal com-
partment appear to be largely context dependent [24,25]. Further,
restoration of GJIC appears to reduce metastatic ability of cancer
cells in some cases [26,27]. The ability of clinically used pharmaco-
logic agents to alter GJIC in cultured astrocytes was the ﬁrst indica-
tion to topically relate the pharmacology of sulfonylureas with
speciﬁc alterations in GJIC [13].
Increased risk for cancer in patients with Type-2 diabetes is
thought to be mediated through the development of metabolic
syndrome which encompasses hyperinsulinemia and insulinFig. 2. KATP inhibitors with SUR2 speciﬁcity increase GJIC in MDA-MB-231. Flow cytometr
cells after 6 h co-culture. Results are represented as fold change between non-treated (
speciﬁcity did not increase GJIC in MDA-MB-231, experiments were performed as d
chlorpropamide (10, 25, 50 lmol/l). (B) Treatment with glimepiride and repaglinide (10
does not increase GJIC in MDA-MB-231. Cells were treated with increasing concentration
described. Minor decreases in GJIC were observed in a dose dependent manner. NT, nonresistance [28,29]. Sulfonylureas are used as a treatment
option for Type-2 diabetes, and recent reports show epidemiolog-
ical evidence for increased cancer-related mortality in patients
treated with sulfonylureas rather than biguanides [19]. In this
report, we demonstrate that treatment of cancer cells in vitro with
sulfonylureas results in a consistent increase in GJIC, a phenome-
non that has been associated with a reduction in metastatic
potential [6,9,23,24,26,27]. Our results highlight a germane
paradox where a supposed reduction in metastatic potential due
to increased GJIC conﬂicts with clinical data showing increased
mortality from the use of sulfonylurea agents. Importantly, our
results appear to indicate that further investigation needs to
address speciﬁc mediators and context dependency rather than
the generic process of GJIC itself between cancer cells.y quantiﬁcation of calcein/DiI assays measuring dye transfer from donor to acceptor
NT) and increasing concentrations of KATP inhibitors. (A) KATP inhibitors with SUR1
escribed in Fig. 1 with increasing concentrations of tolbutamide, gliclazide and
, 25, 50 lmol/l) signiﬁcantly increased GJIC. (C) KATP inhibitor cibenzoline succinate
s of cibenzoline succinate (50, 100, 200 lmol/L) and GJIC assays were performed as
-treated. (⁄P < 0.05, ⁄⁄P < 0.01, error bars represent mean ± standard deviation).
Fig. 4. SUR1 and SUR2 protein expression in SUM159. (A) Whole cell lysates from the SUM159 cell line were analyzed via immunoblot analysis for SUR1 and SUR2. SUR1
protein levels were readily detected while SUR2 expression was low by comparison to MDA-MB-231, MDA-MB-435 and C8161.9 probed under the same conditions. (B)
Quantiﬁed data from GJIC assays demonstrating changes in GJIC with increasing concentrations (10, 25, 50 lmol/l) of gliclazide, chlorpropamide, glimepiride and
glibenclamide. Signiﬁcant increases in GJIC were observed with glimepiride and glibenclamide treatments with no increases during treatment with gliclazide and
chlorpropamide, similar to results obtained from MDA-MB-231, MDA-MB-435 and C8161.9. (⁄P < 0.05, ⁄⁄P < 0.01, error bars represent mean ± standard deviation.)
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tolbutamide and chlorpropamide and second generation agents gli-
benclamideandgliclazide. To initiallyevaluate the effect of sulfonyl-
ureas on GJIC, metastatic cancer cell lines of breast andmelanocytic
origin which exhibit basally low gap junction couplingwere treated
with 10 lmol/l of glibenclamide. A consistent increase in GJIC as
measured by the passage of ﬂuorescent calcein dye passing from la-
beled donor cells to co-cultured acceptor cells over 6 hwas observed
visually (Fig. 1A) and quantiﬁed by ﬂow cytometry (Fig. 1B). Since
glibenclamide consistently increased GJIC following KATP channel
inhibitor treatment, the metastatic breast cancer cell line MDA-
MB-231wasutilized for further investigation. Similar to theaddition
of glibenclamide, treatment of MDA-MB-231 cells with glimepiride
(a sulfonylureaKATP channel inhibitor) and repaglinide, an unrelated
meglitinide class KATP channel inhibitor resulted in a dose-depen-
dent increase in the passage of calcein from labeled donor cells to
acceptor cells indicative of increased GJIC (Fig. 2B). These results ta-
ken together initially indicated that an increase in GJIC may be
dependent on inhibition of KATP channels and independent of struc-
ture and therefore class of these inhibitors.
Treatment of MDA-MB-231 cells with tolbutamide, gliclazide,
and chlorpropamide failed to cause a consistent increase in GJIC
(Fig. 2A). Glibenclamide, glimepiride and repaglinide show compa-
rable efﬁcacy in the inhibition of SUR1 and SUR2, while tolbuta-
mide, gliclazide, and chlorpropamide are selective for SUR1
inhibition at low doses, suggesting a possible differentiation of ef-
fects through these different agents (references for speciﬁcities of
compounds [30–33], summarized in [34]). To determine the
expression of SUR1 and SUR2, whole cell lysates from MDA-MB-
231, MDA-MB-435, and C8161.9 cells were probed with antibodies
directed towards SUR1 and SUR2. SUR2 was evident in each cell
line, while expression of SUR1 could not be detected in MDA-
MB-231 and MDA-MB-435 with low levels of detection in
C8161.9 (Fig. 3). These results suggested a mechanistic explanation
for the pattern of GJIC changes observed following treatment with
KATP inhibitors speciﬁc for SUR1 and SUR2, and why we did not ob-
serve a consistent increase in GJIC with tolbutamide (although
used at lower concentrations in our studies (i.e., 50 lmol/l vs.
400 lmol/l)). KATP channels of the SUR2 subtype (SUR2A, SUR2B)
are most commonly paired with KIR6.2 channels as in cardiac, skel-
etal, and smooth muscle. However, although expression analysis of
KIR subunits was not performed in this study, treatment of MDA-
MB-231 with cibenzoline succinate (50–200 lmol/l), a KATP inhib-
itor that binds directly to the KIR subunit [35], did not induce GJIC,
but rather slightly decreased GJIC levels (Fig. 2C), suggesting possi-
ble secondary effects on GJIC of glibenclamide, glimepiride and
repaglinide that are not related to the inhibition of KATP channels.To further explore this possibility, we used the SUM159 breast
cancer cell line which expresses inverse levels of SUR1 and SUR2
by comparison to MDA-MB-231, MDA-MB-435 and C8161.9
(Fig. 4A). Interestingly, treatment of SUM159 with the SUR1 spe-
ciﬁc KATP channel inhibitors chlorpropamide and gliclazide (10,
25, 50 lmol/l) failed to induce GJIC while glibenclamide and glim-
epiride (10, 25, 50 lmol/l) signiﬁcantly increased GJIC similar to
treatment in MDA-MB-231, MDA-MB-435 and C8161.9 (Fig. 4B).
Although an explanation for the latter result could indicate that
inhibition of SUR1 KATP in SUM159 by glibenclamide and gimepi-
ride was responsible for GJIC, failure of chlorpropamide and glicla-
zide to increase GJIC contradicts these results. The data propose the
possibility of novel KATP independent effects on GJIC by glibencla-
mide, repaglinide and glimepiride. A second explanation would
be that inhibition of the levels of SUR2 expressed in SUM159 is suf-
ﬁcient to increase GJIC but that this effect is not shared by inhibi-
tion of SUR1, although the SUR1 speciﬁc inhibitor tolbutamide has
been shown to increase GJIC in other cell types [15–18], suggesting
possible cell context speciﬁcities.
In addition to the complexity of KATP channel composition,
the roles of KATP channels located other than the cell membrane
in the mitochondria, sarcolemma, and nucleus beg further inves-
tigation, although our preliminary results involving the treat-
ment of cells with 5-hydroxydecanoate (30–300 lmol/l), a
compound with speciﬁcity towards the mitochondrial-KATP chan-
nel produced no effect on GJIC in our experiments (data not
shown). Although much work remains to further understand
the role of KATP channels with GJIC and importantly in identify-
ing the key players that deﬁne a paradoxical relationship be-
tween pharmacological KATP channel inhibition and patient
outcome, especially in cancer, we report that KATP inhibitors with
SUR2 speciﬁcity increase GJIC independently of differences in
SUR1 and SUR2 expression between cell lines and warrant fur-
ther molecular investigation. Our results provoke thought in
the role of conventional therapy not only for the treatment of
Type-2 diabetes, but also cancer and eventual metastasis.
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